» Articles » PMID: 18297169

Vaccination Greatly Reduces Disease, Disability, Death and Inequity Worldwide

Overview
Specialty Public Health
Date 2008 Feb 26
PMID 18297169
Citations 461
Authors
Affiliations
Soon will be listed here.
Abstract

In low-income countries, infectious diseases still account for a large proportion of deaths, highlighting health inequities largely caused by economic differences. Vaccination can cut health-care costs and reduce these inequities. Disease control, elimination or eradication can save billions of US dollars for communities and countries. Vaccines have lowered the incidence of hepatocellular carcinoma and will control cervical cancer. Travellers can be protected against "exotic" diseases by appropriate vaccination. Vaccines are considered indispensable against bioterrorism. They can combat resistance to antibiotics in some pathogens. Noncommunicable diseases, such as ischaemic heart disease, could also be reduced by influenza vaccination. Immunization programmes have improved the primary care infrastructure in developing countries, lowered mortality in childhood and empowered women to better plan their families, with consequent health, social and economic benefits. Vaccination helps economic growth everywhere, because of lower morbidity and mortality. The annual return on investment in vaccination has been calculated to be between 12% and 18%. Vaccination leads to increased life expectancy. Long healthy lives are now recognized as a prerequisite for wealth, and wealth promotes health. Vaccines are thus efficient tools to reduce disparities in wealth and inequities in health.

Citing Articles

Modifiable risk factors of vaccine hesitancy: insights from a mixed methods multiple population study combining machine learning and thematic analysis during the COVID-19 pandemic.

Ebrahimi O, Sandbakken E, Moss S, Johnson S, Hoffart A, Bauermeister S BMC Med. 2025; 23(1):155.

PMID: 40075423 PMC: 11905715. DOI: 10.1186/s12916-025-03953-y.


Temporal trends of avoidable mortality among children under-five in China from 2004 to 2021.

Wang Y, Zhang Y, Wang Y, Hou Y, Wang K Pediatr Res. 2025; .

PMID: 40055535 DOI: 10.1038/s41390-025-03979-1.


'It was just the given thing to do': exploring enablers for high childhood vaccination uptake in East London's Bangladeshi community-a qualitative study.

Ali I, Bell S, Mounier-Jack S BMJ Public Health. 2025; 3(1):e001004.

PMID: 40017957 PMC: 11812862. DOI: 10.1136/bmjph-2024-001004.


[Determinants of vaccine acceptance in Makokou, Gabon].

Bisvigou U, Ngoungou E, Rogombe S, Nzondo S, Ibinga E Pan Afr Med J. 2025; 49:71.

PMID: 39989941 PMC: 11845999. DOI: 10.11604/pamj.2024.49.71.41612.


Preventing vaccine drop-outs: Geographic and system-level barriers to full immunization coverage among children in Uttar Pradesh, India.

Prakash R, Kumar P, Dehury B, Thacker D, Shoemaker E, Manjappa R Vaccine X. 2025; 23:100613.

PMID: 39980605 PMC: 11840531. DOI: 10.1016/j.jvacx.2025.100613.


References
1.
Kirk G, Lesi O, Mendy M, Akano A, Sam O, Goedert J . The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004; 39(1):211-9. DOI: 10.1002/hep.20027. View

2.
Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen O . Mumps and rubella eliminated from Finland. JAMA. 2000; 284(20):2643-7. DOI: 10.1001/jama.284.20.2643. View

3.
Schmitt H, von Konig C, Neiss A, Bogaerts H, Bock H, Schulte-Wissermann H . Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996; 275(1):37-41. View

4.
Cutts F, Zaman S, Enwere G, Jaffar S, Levine O, Okoko J . Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005; 365(9465):1139-46. DOI: 10.1016/S0140-6736(05)71876-6. View

5.
Aristegui J, Usonis V, Coovadia H, Riedemann S, Win K, Gatchalian S . Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J Infect Dis. 2003; 7(2):143-51. DOI: 10.1016/s1201-9712(03)90011-7. View